Peroxisome proliferator-activated receptor ligands in atherosclerosis

Expert Opinion on Investigational Drugs

Volumn 13, Issue 11, 2004, Pages 1393-1403

  Viles Gonzalez, Juan F ^a   Choi, Brian G ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Fibrate; PPAR; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CD36 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LIGAND; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; TROGLITAZONE; UNINDEXED DRUG;

ATHEROSCLEROSIS; BINDING AFFINITY; CLINICAL STUDY; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEART PROTECTION; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIUM; HUMANS; LIGANDS; MYOCARDIUM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 8844274788     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.11.1393     Document Type: Review

References (103)

1. BRAISSANT O, FOUFELLE F, SCOTTO C, DAUCA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology (1996) 137:354-356.
2. PLUTZKY J: Medicine. PPARs as therapeutic targets: reverse cardiology? Science (2003) 302:406-407.
3. RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341:410-418.
4. CHOI SH, CHOI DH, KO YK: Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with Type 2 diabetes. Diabetes (2003) 52:A19.
5. KOSHIYAMA H, SHIMONO D, KUWAMURA N, MINAMIKAWA J, NAKAMURA Y: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocinol. Metab. (2001) 86:3452-3456.
6. SIDHU JS, COWAN D, KASKI JC: Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am. J. Cardiol. (2004) 94:151-156.
7. VILES-GONZALEZ JF, FUSTER V, BADIMON JJ: Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur. Heart J. (2004) 25:1197-207.
8. VILES-GONZALEZ JF, ANAND SX, VALDIVIEZO C et al.: Update in atherothrombotic disease. Mt. Sinai J. Med. (2004) 71 197-208.
9. VILES-GONZALEZ JF, BADIMON JJ: Atherothrombosis: the role of tissue factor. Int. J. Biochem. Cell Biol. (2004) 36:25-30.
10. PLUTZKY J: Peroxisome proliterator-activated receptors as therapeutic targets in inflammation. J. Am. Coll. Cardiol. (2003) 42:1764-1766.
11. CORTI R, FUSTER V, BADIMON JJ: Pathogenetic concepts of acute coronary syndromes. J. Am. Coll. Cardiol. (2003) 41:7S-14S.
12. PETERS HARMEL AL, KENDALL DM, BUSE JB, BOYLE PJ, MARCHETTI A, LAU H: Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with Type 2 diabetes. Curr. Med. Res. Opin. (2004) 20:215-223.
13. OLANSKY L, MARCHETTI A, LAU H: Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with Type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin. Ther. (2003) 25(Suppl. B):B64-B80.
14. GEGICK CG, ALTHEIMER MD: Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr. Pract. (2001) 7:162-169.
15. KO SH, SONG KH, AHN YB et al.: The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with Type 2 diabetes mellitus. Metabolism (2003) 52:731-734.
16. FREED MI, RATNER R, MARCOVINA SM et al.: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. Am. J. Cardiol. (2002) 90:947-952.
17. GERBER P, LUBBEN G, HEUSLER S, DODO A: Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with Type 2 diabetes mellitus. Curr. Med. Res. Opin. (2003) 19:532-539.
18. RAJI A, SEELY EW, BEKINS SA, WILLIAMS GH, SIMONSON DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care (2003) 26:172-178.
19. FULLERT S, SCHNEIDER F, HAAK E et al.: Eflects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. (2002) 87:5503-5506.
20. SHARGORODSKY M, WAINSTEIN J, GAVISH D et al.: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with Type 2 diabetes mellitus. Am. J. Hypertens. (2003) 16:617-622.
21. RYAN MJ, DIDION SP, MATHUR S, FARACI FM, SIGMUND CD: PPAR(γ) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension (2004) 43 661-666.
22. LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420:868-874.
23. CALNEK DS, MAZZELLA L, ROSER S, ROMAN J, HART CM: Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. (2003) 23:52-57.
24. TAO L, LIU HR, GAO E et al.: Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circulation (2003) 108:2805-2811.
25. SCHAAR JA, MULLER JE, FALK E et al.: Terminology for high-risk and vulnerable coronary artery plaques. Eur. Heart J. (2004) 25:1077-1082.
26. MALLAT Z, TEDGUI A: Current perspective on the role of apoptosis in atherothrombotic disease. Circ. Res. (2001) 88 998-1003.
27. HUTTER R, VALDIVIEZO C, SAUTER BV et al.: Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation (2004) 109:2001-2008.
28. PHILLIPS JW, BARRINGHAUS KG, SANDERS JM et al.: Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of Type 2 diabetes. Circulation (2003) 108:1994-1999.
29. KANEHARA H, TOHDA G, OIDA K, SUZUKI J, ISHII H, MIYAMORI I: Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. Thromb. Res. (2002) 108 227-234.
30. HAFFNER SM, GREENBERG AS, WESTON WM, CHEN H, WILLIAMS K, FREED MI: Effect of rosiglitazone treatment on nontraditional markets of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106:679-684.
31. HETZEL M, WALCHER D, GRUB M, BACH H, HOMBACH V, MARX N: Inhibition of MMP-9 expression by PPARγ activators in human bronchial epithelial cells. Thorax (2003) 58:778-783.
32. DONG FQ, LI H, CAI WM et al.: Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin. Med. J. (2004) 117:1040-1044.
33. MARX N, FROEHLICH J, SIAM L et al.: Antidiabetic PPARγ -activator rosiglitazone reduces MMP-9 serum levels in Type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. (2003) 23:283-288.
34. NEVE BP, CORSEAUX D, CHINETTI G et al.: PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation (2001) 103:207-212.
35. CHEN Z, ISHIBASHI S, PERREY S et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. (2001) 21:372-377.
36. GIBBONS GH, PRATT RE, DZAU VJ: Vascular smooth muscle cell hypertrophy versus hyperplasia. Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J. Clin. Invest. (1992) 90:456-461.
37. DIEP QN, EL MABROUK M, COHN JS et al.: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation (2002) 105:2296-2302.
38. TAKEDA K, ICHIKI T, TOKUNOU T et al.: Peroxisome proliferator-activatcd receptor γ activators downregulate angiotensin II Type 1 receptor in vascular smooth muscle cells. Circulation (2000) 102:1834-1839.
39. PERSHADSINGH HA: Peroxisome proliferator-activated receptof-γ: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Investig. Drugs (2004) 13:215-228.
40. DESOUZA CV, MURTHY SN, DIEZ J et al.: Differential effects of peroxisome proliferator activator receptor-α and γ ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J. Cardiovasc. Pharmacol. Ther. (2003) 8 297-305.
41. JARVISALO MJ, RAITAKARI M, TOIKKA JO et al.: Endothelial dysfunction and increased arterial intima-media thickness in children with Type 1 diabetes. Circulation (2004) 109 1750-1755.
42. DE DIOS ST, BRUEMMER D, DILLEY RJ et al.: Inhibitory activity of clinical thiazolidinedione pcroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation (2003) 107:2548-2550.
43. CORTI R, FUSTER V, FAYAD ZA et al.: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 106:2884-2887.
44. CORTI R, OSENDE JI, FALLON JT et al.: The selective peroxisomal proliferator-activated receptor-γ agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. (2004) 43 464-473.
45. HERZ M, JOHNS D, REVIRIEGO J et al.: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with Type 2 diabetes mellitus. Clin. Ther. (2003) 25:1074-1095.
46. FRICK MH, ELO O, HAAPA K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. (1987) 317 1237-1245.
47. MANNINEN V, TENKANEN L, KOSKINEN P et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 85 37-45.
48. ERICSSON CG, HAMSTEN A, NILSSON J, GRIP L, SVANE B, DE FAIRE U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet (1996) 347:849-853.
49. Secondary Prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102 21-27.
50. OLIVER WR Jr, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98 5306-5311.
51. CHINETTI G, LESTAVEL S, BOCHER V et al.: PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. (2001) 7:53-58.
52. MINNICH A, TIAN N, BYAN L, BILDER G: A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle. Am. J. Physiol. Endocrinol Metab. (2001) 280 E270-E279.
53. TAKAGI T, YAMAMURO A, TAMITA K et al.: Impact of troglitazone on coronary stent implantation using small stents in patients with Type 2 diabetes mellitus. Am. J. Cardiol. (2002) 89:318-322.
54. TAKAGI T, YAMAMURO A, TAMITA K et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with Type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am. Heart J. (2003) 146:E5.
55. MORIKANG E, BENSON SC, KURTZ TW, PERSHADSINGH HA: Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am. J. Hypertens. (1997) 10:440-446.
56. VIRMANI R, KOLODGIE FD, BURKE AP, FARB A, SCHWARTZ SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1262-1275.
57. FUSTER V, CORTI R, FAYAD ZA, SCHWITTER J, BADIMON JJ: Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. J. Thromb. Haemost. (2003) 1:1410-1421.
58. LIBBY P, RIDKER PM: Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. (2004) 116 Suppl. 6A):9S-16S.
59. SWEETNAM PM, THOMAS HF, YARNELL JW, BAKER IA, ELWOOD PC: Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am. J. Epidemiol. (1997) 145:416-421.
60. ROSS R: Atherosclerosis-an inflammatory disease. N. Engl. J. Med. (1999) 340:115-126.
61. IIDA KT, KAWAKAMI Y, SUZUKI M et al.: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E1125-E1130.
62. COMINACINI L, GARBIN U, PASINI AF et al.: The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhes. Commun. (1999) 7:223-231.
63. LEE CH, CHAWLA A, URBIZTONDO N et al.: Transcriptional repression of atherogenic inflammation: modulation by PPAR-δ. Science (2003) 302:453-457.
64. MARX N, SUKHOVA GK, COLLINS T, LIBBY P, PLUTZKY J: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 99 3125-3131.
65. GRAHAM IM, DALY LE, REFSUM HM et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA (1997) 277:1775-1781.
66. ZENG X, DAI J, REMICK DG, WANG X: Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ. Res. (2003) 93 311-320.
67. ANAND SX, VILES-GONZALEZ JF, BADIMON JJ, CAVUSOGLU E, MARMUR JD: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb. Haemost. (2003) 90:377-384.
68. VARO N, DE LEMOS JA, LIBBY P et al.: Soluble CD40L: risk prediction after acute coronary syndromes. Circulation (2003) 108:1049-1052.
69. VARO N, VICENT D, LIBBY P et al.: Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation (2003) 107:2664-2669.
70. HEESCHEN C, DIMMELER S, HAMM CW et al.: Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. (2003) 348 1104-1111.
71. MARX N, IMHOF A, FROEHLICH J et al.: Effect of rosiglitazone treatment on soluble CD40L in patients with Type 2 diabetes and coronary artery disease. Circulation (2003) 107 1954-1957.
72. AKBIYIK F, RAY DM, GETTINGS KF, BLUMBERG N, FRANCIS CW, PHIPPS RP: Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood (2004) 104:1361-1368.
73. SIDHU JS, COWAN D, TOOZE JA, KASKI JC: Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am. Heart J. (2004) 147:e25.
74. LINDAHL B, TOSS H, SIEGBAHN A, VENGE P, WALLENTIN L: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coron. Artery Dis. N. Engl. J. Med. (2000) 343 1139-1147.
75. SATOH N, OGAWA Y, USUI T et al.: Antiatherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. (2003) 26:2493-2499.
76. SIDHU JS, COWAN D, KASKI JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on markets of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol. (2003) 42:1757-1763.
77. RAUCH U, CRANDALL J, OSENDE JI et al.: Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus Type 2. Am. J. Cardiol. (2000) 86 246-249.
78. CUZZOCREA S, PISANO B, DUGO L et al.: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur J. Pharmacol. (2004) 483:79-93.
79. CUZZOCREA S, PISANO B, DUGO L et al.: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of nonseptic shock induced by zymosan in mice. Crit. Care Med. (2004) 32:457-466.
80. SAMBOLA A, OSENDE J, HATHCOCK J et al.: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation (2003) 107:973-977.
81. OSENDE JI, BADIMON JJ, FUSTER V et al.: Blood thrombogenicity in Type 2 diabetes mellitus patients is associated with glycemic control. J. Am. Coll. Cardiol. (2001) 38:1307-1312.
82. NAGHAVI M, LIBBY P, FALK E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation (2003) 108 1772-1778.
83. YUE TL TL, CHEN J, BAO W et al.: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation (2001) 104:2588-2594.
84. ITO H, NAKANO A, KINOSHITA M, MATSUMORI A: Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest. (2003) 83:1715-21.
85. SIVARAJAH A, CHATTERJEE PK, PATEL NS et al.: Agonists of peroxisome-proliferator activated recepror-γ reduce renal ischemia/reperfusion injury. Am. J. Nephrol. (2003) 23 267-276.
86. SHIOMI T, TSUTSUI H, HAYASHIDANI S et al.: Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2002) 106:3126-3132.
87. MARTIN-NIZARD F, FURMAN C, DELERIVE P et al.: Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J. Cardiovasc. Pharmacol. (2002) 40:822-831.
88. DELERIVE P, MARTIN-NIZARD F, CHINETTI G et al.: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. (1999) 85:394-402.
89. YANG LL, GROS R, KABIR MG et al.: Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation (2004) 109:255-261.
90. IGLARZ M, TOUYZ RM, AMIRI F, LAVOIE MF, DIEP QN, SCHIFFRIN EL: Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. (2003) 23:45-51.
91. GHAZZI MN, PEREZ JE, ANTONUCCI TK et al.: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes (1997) 46:433-439.
92. OGINO K, FURUSE Y, UCHIDA K et al.: Troglitazone improves cardiac function in patients with congestive heart failure. Cardiovasc. Drugs Ther. (2002) 16:215-220.
93. WANG CH, WEISEL RD, LIU PP, FEDAK PW, VERMA S: Glitazones and heart failure: critical appraisal for the clinician. Circulation (2003) 107:1350-1354.
94. LEBOVITZ HE, DOLE JF, PATWARDHAN R, RAPPAPORT EB, FREED MI: Rosiglitazone Clinical Trials Study Group: rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86:280-288.
95. FONSECA V, ROSENSTOCK J, PATWARDHAN R, SALZMAN A: Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomized controlled trial. JAMA (2000) 283:1695-1702.
96. GOMEZ-PEREZ FJ, FANGHANEL-SALMON G, ANTONIO BARBOSA J et al.: Efficacy and safety of rosiglitazone plus metformin in Mexicans with Type 2 diabetes. Diabetes Metab. Res. Rev. (2002) 18 127-134.
97. VONGTHAVARAVAT V, WAJCHENBERG BL, WAITMAN JN et al.: 125 Study Group: an international study of the effects of rosiglitazone plus sulphonylurea in patients with Type 2 diabetes. Curr. Med. Res. Opin. (2002) 18:456-461.
98. RASIGN P, RENDELL M, RIDDLE MC, DOLE JF, FREED MI, ROSENSTOCK J: Rosiglitazone Clinical Trials Study Group: a randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated Type 2 diabetes. Diabetes Care (2001) 24 1226-1232.
99. ARONOFF S, ROSENBLATT S, BRAITHWAITE S, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care (2000) 23:1605-1611.
100. ROSENBLATT S, MISKIN B, GLAZER NB, PRINCE MJ, ROBERTSON KE: Pioglitazone 026 Study Group: the impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis. (2001) 12:413-423.
101. EINHORN D, RENDELL M, ROSENZWEIG J, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride in combination with metformin in the treatment of Type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. (2000) 22:1395-1409.
102. KIPNES MS, KROSNICK A, RENDELL MS, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with Type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. (2001) 111:10-17.
103. ROSENSTOCK J, EINHORN D, HERSHON K, GLAZER NB, YU S: Pioglitazone 014 Study Group: efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy Int. J. Clin. Pract. (2002) 56 251-257.